TCG Crossover GP II Reports 7.9% Stake in Fulcrum Therapeutics, Inc. via Schedule 13G/A

TCG Crossover GP II, LLC and its affiliates, including TCG Crossover Fund II, L.P. and Chen Yu, filed an Amendment No. 1 to their Schedule 13G regarding their holdings in Fulcrum Therapeutics, Inc. (FULC). As of the event date on March 31, 2026, the reporting persons collectively hold 5,250,000 shares of common stock, representing a 7.9% ownership stake based on 66,633,321 shares outstanding. This filing serves as an update to the original Schedule 13G filed in September 2024. The shares are held of record by TCG Crossover II, with TCG Crossover GP II serving as the general partner and Chen Yu as the sole managing member. The reporting persons have shared voting and dispositive power over the reported shares. The filing includes a certification that the shares were not acquired for the purpose of changing or influencing the control of the issuer. The principal business office for the reporting entities is located in Palo Alto, California.